ストックスクリーナーアプリを入手
39.93
0.81%
0.2929
前日終値:
$39.64
開ける：
$39.95
24時間の取引高:
581.55K
Relative Volume:
0.71
時価総額：
$3.08B
収益：
$13.17M
当期純損益:
$-199.06M
株価収益率:
-14.57
EPS:
-2.74
ネットキャッシュフロー:
$-156.53M
1週間 パフォーマンス:
+1.04%
1か月 パフォーマンス:
+10.36%
6か月 パフォーマンス:
+27.26%
1年 パフォーマンス:
-3.03%
1日の値動き範囲:
$39.34
$41.00
1週間の範囲:
$38.49
$41.66
52週間の値動き範囲:
$26.74
$46.00
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
名前
Xenon Pharmaceuticals Inc
セクター
電話
(604) 484-3300
住所
200 - 3650 GILMORE WAY, BURNABY
XENE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
39.95 | 3.06B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.10 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
471.80 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.88 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
804.49 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
328.98 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-03 | 再開されました | Wells Fargo | Overweight |
| 2025-05-07 | 開始されました | Chardan Capital Markets | Buy |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-10-01 | 開始されました | H.C. Wainwright | Buy |
| 2024-01-04 | 開始されました | Citigroup | Buy |
| 2023-12-08 | 開始されました | Robert W. Baird | Outperform |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-04-25 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-14 | 開始されました | Goldman | Buy |
| 2022-12-12 | 開始されました | Cowen | Outperform |
| 2022-11-28 | 開始されました | Wells Fargo | Overweight |
| 2022-10-19 | 開始されました | Raymond James | Outperform |
| 2022-08-29 | 開始されました | BofA Securities | Buy |
| 2022-07-21 | 開始されました | JP Morgan | Overweight |
| 2021-10-28 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-10-02 | 開始されました | SVB Leerink | Outperform |
| 2020-07-21 | 開始されました | Needham | Buy |
| 2020-06-01 | 再開されました | Jefferies | Buy |
| 2020-03-25 | 開始されました | Wedbush | Outperform |
| 2020-01-08 | 開始されました | William Blair | Outperform |
| 2019-09-20 | 開始されました | Guggenheim | Buy |
| 2018-08-08 | 繰り返されました | Stifel | Buy |
| 2017-03-13 | 開始されました | Jefferies | Buy |
| 2016-10-21 | 開始されました | Stifel | Buy |
| 2016-09-26 | 開始されました | Guggenheim | Buy |
| 2016-04-14 | 繰り返されました | Jefferies | Buy |
| 2015-10-30 | 再開されました | Jefferies | Buy |
| 2014-12-02 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Xenon Pharmaceuticals Inc (XENE) 最新ニュース
Will Xenon Pharmaceuticals Inc. price bounce be sustainableJuly 2025 Update & Trade Opportunity Analysis - newser.com
Published on: 2025-10-13 08:53:34 - newser.com
Xenon Pharmaceuticals Inc.’s volatility index tracking explainedMarket Performance Report & Fast Gain Stock Trading Tips - newser.com
Will Xenon Pharmaceuticals Inc. stock attract more institutional investorsWeekly Trade Recap & Entry Point Confirmation Alerts - newser.com
Xenon Pharmaceuticals (XENE): Exploring Valuation After Recent Share Price Momentum - Yahoo
Leerink Partners Remains a Buy on Xenon (XENE) - The Globe and Mail
Research Analysts Issue Forecasts for XENE FY2025 Earnings - MarketBeat
What is Bloom Burton’s Estimate for XENE FY2025 Earnings? - Defense World
Xenon Pharmaceuticals Issues Equity Inducement Grants to New Employees - MSN
Will Xenon Pharmaceuticals Inc. stock attract ESG investorsDay Trade & Free Weekly Watchlist of Top Performers - newser.com
Is Xenon Pharmaceuticals Inc. stock attractive for income investors2025 Trading Recap & Capital Efficiency Focused Ideas - newser.com
What analysts say about Xenon Pharmaceuticals Inc stockInsider Selling Patterns & Budget Friendly Trading Strategies - earlytimes.in
Brokers Offer Predictions for XENE FY2026 Earnings - MarketBeat
Bloom Burton Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to "Strong-Buy" - MarketBeat
Xenon Pharmaceuticals’ (XENE) Outperform Rating Reaffirmed at William Blair - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Given “Buy” Rating at Chardan Capital - Defense World
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
77,750 Options: Xenon Pharmaceuticals Grants Equity to Seven New Hires at $39.20, Oct 2, 2025 - Stock Titan
Xenon Pharmaceuticals' (XENE) Outperform Rating Reiterated at William Blair - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Receives "Buy" Rating from Chardan Capital - MarketBeat
XENE: Chardan Capital Maintains Buy Rating with $55 Price Target | XENE Stock News - GuruFocus
Chardan Capital Maintains Xenon Pharmaceuticals (XENE) Buy Recommendation - Nasdaq
Transcript : Xenon Pharmaceuticals Inc.Special Call - MarketScreener
Will Xenon Pharmaceuticals Inc. stock recover after recent dropJobs Report & Verified Swing Trading Watchlist - newser.com
Is it time to cut losses on Xenon Pharmaceuticals Inc.Market Growth Summary & Safe Capital Investment Plans - newser.com
Xenon Pharmaceuticals Inc. $XENE Shares Purchased by J. Safra Sarasin Holding AG - MarketBeat
Xenon Pharmaceuticals announces executive changes - MSN
HighMark Wealth Management LLC Has $817,000 Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Inc. stock chart pattern explainedWeekly Volume Report & Low Risk Entry Point Tips - newser.com
Will Xenon Pharmaceuticals Inc. stock maintain growth storyGap Down & Free AI Powered Buy and Sell Recommendations - newser.com
Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE) - MarketBeat
Insider Selling: Xenon Pharmaceuticals (NASDAQ:XENE) CEO Sells 25,000 Shares of Stock - MarketBeat
Xenon Pharmaceuticals Hits Day High with Strong 9.94% Intraday Surge - Markets Mojo
Published on: 2025-10-01 07:26:08 - newser.com
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat
Xenon Pharmaceuticals Inc (XENE) 財務データ
収益
当期純利益
現金流量
EPS
Xenon Pharmaceuticals Inc (XENE) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| MORTIMER IAN | PRESIDENT, CEO & INTERIM CFO |
Oct 01 '25 |
Sale |
40.16 |
25,000 |
1,004,000 |
31,302 |
1.18%
大文字化:
|
ボリューム (24 時間):